- Home
- PIM vs ACHV Comparison
PIM vs ACHV Comparison
Compare PIM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- ACHV
- Stock Information
- Founded
- PIM 1988
- ACHV N/A
- Country
- PIM United States
- ACHV United States
- Employees
- PIM N/A
- ACHV N/A
- Industry
- PIM Finance Companies
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PIM Finance
- ACHV Health Care
- Exchange
- PIM Nasdaq
- ACHV Nasdaq
- Market Cap
- PIM 168.6M
- ACHV 131.3M
- IPO Year
- PIM N/A
- ACHV N/A
- Fundamental
- Price
- PIM $3.48
- ACHV $2.96
- Analyst Decision
- PIM
- ACHV Strong Buy
- Analyst Count
- PIM 0
- ACHV 2
- Target Price
- PIM N/A
- ACHV $16.00
- AVG Volume (30 Days)
- PIM 57.5K
- ACHV 1.6M
- Earning Date
- PIM 01-01-0001
- ACHV 11-06-2025
- Dividend Yield
- PIM 8.28%
- ACHV N/A
- EPS Growth
- PIM N/A
- ACHV N/A
- EPS
- PIM 0.05
- ACHV N/A
- Revenue
- PIM N/A
- ACHV N/A
- Revenue This Year
- PIM N/A
- ACHV N/A
- Revenue Next Year
- PIM N/A
- ACHV N/A
- P/E Ratio
- PIM $63.80
- ACHV N/A
- Revenue Growth
- PIM N/A
- ACHV N/A
- 52 Week Low
- PIM $2.90
- ACHV $1.84
- 52 Week High
- PIM $3.28
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- PIM 67.08
- ACHV 51.21
- Support Level
- PIM $3.43
- ACHV $2.97
- Resistance Level
- PIM $3.50
- ACHV $3.30
- Average True Range (ATR)
- PIM 0.04
- ACHV 0.21
- MACD
- PIM 0.01
- ACHV -0.01
- Stochastic Oscillator
- PIM 89.41
- ACHV 45.16
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.